12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Canagliflozin: Phase III data

The double-blind, international Phase III DIA3015 trial in 755 Type II diabetics with inadequate glycemic control on maximally effective doses of metformin and sulfonylurea showed that once-daily 300 mg oral canagliflozin plus metformin and sulfonylurea met the primary endpoint of reducing HbA1c from baseline to week 52 vs. once-daily 100 mg Januvia sitagliptin plus metformin and sulfonylurea (1.03% vs. 0.66%). On secondary endpoints, canagliflozin led to significantly greater reductions in FPG (29.9...

Read the full 350 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >